Fintel reports that on February 13, 2025, Cantor Fitzgerald initiated coverage of GH Research (NasdaqGM:GHRS) with a ...

GH Research PLC (NASDAQ:GHRS) has received an Overweight rating from Cantor Fitzgerald, with a price target set at $14.00. The new coverage is based on the potential of GHRS's GH001, an inhaled ...

Cantor Fitzgerald initiated coverage of GH Research (GHRS) with an Overweight rating and $14 price target Maximize Your Portfolio with Data ...

FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.

Key Insights GH Research's significant insider ownership suggests inherent interests in company's expansion A total ...

Shares of GH Research PLC GHRS have rallied 54.8% in a week after the company, on Feb. 3, 2025, announced that it has met the ...

We recently compiled a list of the Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025. In this article, we are ...

In a report released today, Jason Butler from JMP Securities reiterated a Buy rating on GH Research (GHRS – Research Report), with a price ...

Owens & Minor, Inc. OMI shares dropped 32% to $9.68 after the company issued lower-than-expected fourth-quarter and FY24 ...

The company earlier announced that the primary endpoint was met in a randomized, double-blind, placebo-controlled Phase IIb ...

GH Research's Phase 2b trial of GH001 for treatment-resistant depression met its primary endpoint, showing significant efficacy and a favorable safety profile.